Evaluation Of The Clinical Efficacy And Safety Of Dexlansoprazole For Different Doses Of Injection In The Treatment Of Peptic Ulcer Bleeding

[Objective]To explore the effectiveness and safety of different doses of dexlansoprazole for injection in the treatment of peptic ulcer bleeding,and to provide references for clinical rational drug use.[Methods]Selected patients with gastrointestinal bleeding from August 2019 to December2020 who were hospitalized in the Gastroenterology Department of Yichun People’s hospital due to hematemesis or melena.they were confirmed to have peptic ulcer and bleeding by gastroscopy(within 24 hours of admission).A total of 73 patients were included in the study,and all patients were randomly divided into two groups.Among them,There were 28 patients in 15 mg group.the medication regimen was dexlansoprazole MR 15 mg for injection,twice a day for 5 consecutive days;there were 45 patients in 30 mg group.dexlansoprazole MR 30 mg for injection,twice a day for 5 days.Observe the clinical efficacy and the incidence of adverse events in all patients in the group,evaluate the effectiveness and safety of different doses of dexlansoprazole in the treatment of peptic ulcer bleeding,and provide references for clinical rational use of drugs.[Results]1.Comparison of the general conditions of the two groups of patients :Including the age,gender,comorbid diseases,endoscopic grading,helicobacter pylori(HP)infection,bleeding volume,bleeding degree,accompanying symptoms,etc.between the two groups,there was no statistically significant difference between the two groups.2.Comparison of the 72-hour hemostatic effect between the two groups of patient:the 72 h hemostatic rate of the two groups of patients was 100%.3.During the treatment period,the rate of patients in the two groups who required re-endoscopic hemostasis,blood transfusion,and surgery within 5 days was0.00%,and there was no significant difference between the two groups.4.The incidence of adverse reactions in the two groups of patients: 3 cases in the15 mg group,the incidence of adverse reactions was 10.71%,and 5 cases in the 30 mg group,the incidence of adverse events was 11.11%.there was no significant difference between the two groups(χ~2=3.926,P=0.058> 0.05)[conclusion]The clinical efficacy of dexlansoprazole MR for injection 15 mg q12h in peptic ulcer bleeding is equivalent to that of dexlansoprazole MR for injection 30 mg q12h,and its was thought to be effective and safe.